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Abstract
Introduction: The use of methadone as an analgesic is on the increase, but it is widely recognized that the goal
of predictable and reproducible dosing is confounded by considerable variability in methadone pharmacokinetics,
and unpredictable side effects that include sedation, respiratory depression and cardiac arrhythmias. The
mechanisms underlying these unpredictable effects are frequently unclear. Here, to the best of our knowledge we
present the first report of an association between accidental methadone overexposure and increased plasma
protein binding, a new potential mechanism for drug interactions with methadone.
Case presentation: We describe here the cases of two patients who experienced markedly different responses to
the same dose of methadone during co-administration of letrozole. Both patients were post-menopausal Caucasian
women who were among healthy volunteers participating in a clinical trial. Under the trial protocol both patients
received 6 mg of intravenous methadone before and then after taking letrozole for seven days. One woman (aged
59) experienced symptoms consistent with opiate overexposure after the second dose of methadone that were
reversed by naloxone, while the other (aged 49) did not. To understand the etiology of this event, we measured
methadone pharmacokinetics in both patients. In our affected patient only, a fourfold to eightfold increase in
methadone plasma concentrations after letrozole treatment was observed. Detailed pharmacokinetic analysis
indicated no change in metabolism or renal elimination in our patient, but the percentage of unbound
methadone in the plasma decreased 3.7-fold. As a result, the volume of distribution of methadone decreased
approximately fourfold. The increased plasma binding in our affected patient was consistent with observed
increases in plasma protein concentrations.
Conclusions: The marked increase in the total plasma methadone concentration observed in our patient, and the
enhanced pharmacodynamic effect, appear primarily due to a reduced volume of distribution. The extent of
plasma methadone binding may help to explain the unpredictability of its pharmacokinetics. Changes in volume of
distribution due to plasma binding may represent important causes of clinically meaningful drug interactions.
Introduction
The use of methadone as an analgesic is on the increase
[1], but it is widely recognized that the goal of predictable
and reproducible dosing is confounded by considerable
variability in methadone pharmacokinetics [2,3]. The
unpredictability of methadone’se f f e c t sr e s u l t si nah i g h
incidence of inappropriate overdosing and underdosing,
which can lead to severe adverse events including
sedation, respiratory depression and cardiac arrhythmias
[4-6]. Many such events, including death, occur beyond
the reach of medical care or observation. As a result a
complete understanding of the mechanisms underlying
individual adverse events has rarely been possible. We
present here a scenario in which we were able to carefully
investigate the cause of an accidental methadone overex-
posure. To the best of our knowledge this is the first
report of an association between accidental methadone
overexposure and increased plasma protein binding. * Correspondence: lu20@iupui.edu
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We describe here the cases of two patients who experi-
enced markedly different responses to the same dose of
methadone during co-administration of letrozole. Both
patients were post-menopausal Caucasian women who
were among healthy volunteers participating in a clinical
trial (depicted in Table 1). The protocol for this study was
approved by the Indiana University School of Medicine
Institutional review Board (IRB), both patients signed
informed consent before participation in the trial, and all
procedures were conducted in accordance with the guide-
lines of the Declaration of Helsinki. The trial was designed
to test the hypothesis that the aromatase inhibitor, letro-
zole, would alter the pharmacokinetics of methadone,
based on pre-clinical data indicating that methadone is
metabolized by aromatase in vitro [7]. Under the trial pro-
tocol both patients received 6 mg of intravenous metha-
done before, and then after taking letrozole for seven days.
Case 1
Our first patient was a 49-year-old Caucasian woman (69.5
kg, body mass index (BMI) 27.3, taking naproxen) who
responded normally to the administered drugs as
expected, and did not show any clinical adverse reaction
to methadone or letrozole throughout the course of study.
We designated this unaffected patient as ‘N’, and the doses
of methadone administered before and after letrozole as
dose ‘A’ and dose ‘B’ in the subsequent data analyses in
order to compare the results between the two patients. All
plasma and urine samples collected were analyzed as
described in Additional file 1. No significant change in
methadone pharmacokinetics before and after letrozole
treatment was observed in our patient. Pharmacokinetic
data obtained from patient ‘N’ were compared to those
from Case 2 in details as described below.
Case 2
Our second patient was a 59-year-old Caucasian woman
(86.8 kg, BMI 29.2, taking vitamin C, D, E, B6 and cal-
cium). She experienced symptoms consistent with opiate
overexposure that were reversed by naloxone after the sec-
ond dose of methadone. Specific details of this adverse
event, including the hospital course, patient monitoring
data and medication schedule that resulted are illustrated
in Figure 1. We designated our patient, who had experi-
enced the adverse reaction, as ‘ADR’, and the doses of
methadone administered before and after letrozole as dose
‘C’ and dose ‘D’ in the subsequent data analyses. Pharma-
cokinetic data from our ADR patient were compared in
detail to those obtained from our N patient.
No methadone was detected in the plasma before the
administration of intravenous methadone at baseline to
either patient. Methadone plasma concentrations in ADR
after dose D were fourfold to eightfold higher than those
measured after her methadone dose C, given in the
absence of letrozole (Figure 2). The maximum concentra-
tion observed was 135 ng/mL after dose D, while it was
30 ng/mL after dose C. When estimated pharmacokinetic
parameters in our two patients were compared, the area
under the curve (AUC)0-24 h of methadone, its redistribu-
tion half-life, and its volume of distribution (Vd)w e r e
remarkably different after dose D in our ADR patient
when compared to doses A, B and C (Table 2). These data
indicate that there was a fourfold to sixfold decrease in Vd
in our ADR patient after dose D.
The first 12-hour urine volume was much lower in
ADR (dose D; Table 3). The concentration of urinary
methadone after dose D was approximately 13-fold
higher than that after dose C, and the total amount of
methadone excreted was 1.4-fold greater.
The metabolite data from our ADR patient also indi-
cate important differences after dose D, both in the
plasma (Table 2) and in the urine (Table 3). The AUC0-
24 h of plasma 2-ethylidene-1,5-dimethyl-3,3-diphenyl-
pyrrolidine (EDDP; primary metabolite of methadone)
and 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP;
secondary metabolite of methadone) increased approxi-
mately eightfold and approximately sevenfold respec-
tively. The urinary concentration of EDDP increased
approximately 17-fold, and the concentration of EMDP
Table 1 Clinical trial design and schedule of activities
Screening Period I Washout period Period II
Study day -28 to 0 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18
Electrocardiogram for QT interval X
Blood draw for screening X
Methadone dose, 6.0 mg, intravenous X X
Letrozole dose, 2.5 mg, orally once a day X X X X X X X X X X X
Blood draw for pharmacokinetics X X X X X X X X
Urine sampling X X
Blood samples (10 mL each) were collected before and at one, two, four, eight, 12, 24, 48 and 72 hours after each methadone dose, except in the second dose
for our affected patient from whom blood samples at 48 and 72 hours could not be collected. Urine samples were collected at baseline and over the first 12
hours after methadone dose.
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Page 2 of 7Figure 1 Course of the adverse event over the first five hours after the dose of methadone. The white arrows under the name of each
medication indicate their times of administration. Shaded boxes on lines following specific symptoms indicate the times and duration of those
symptoms. Double-headed arrow: during this time, vital signs worsened. The lowest blood pressure recorded was 110/86, respiratory rates as low
as five breaths/minute occurred, and pulse oximetry documented oxygen saturation as low as 75%.
Figure 2 Plasma methadone concentrations after single intravenous doses administered to both patients.A D R=o u rp a t i e n tw h o
experienced methadone overexposure; doses A and C = doses of methadone administered before letrozole treatment; doses B and D = doses
of methadone administered after letrozole treatment; N = our unaffected patient.
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E D D Pa n dE M D Pe x c r e t e di nu r i n ed u r i n gt h ef i r s t1 2
hours were 1.8-fold and 1.3-fold greater respectively
than those after dose C (Table 3).
In order to determine the amount of bound and free
methadone and EDDP in the plasma, we selected samples
collected at eight and 12 hours after the methadone dose,
which is after the redistribution phase assuming a two-
compartment model. In our ADR patient, the mean
methadone fraction unbound (fu) in these samples
decreased 3.7-fold from doses C to D, while the EDDP
fraction unbound decreased 3.6-fold (Table 4).
Table 2 Plasma pharmacokinetic parameters
Parameter N ADR
Dose A Dose B Ratio (B/A) Dose C Dose D Ratio (D/C)
Letrozole Cbaseline (ng/mL) 0 106.9 0 76.1
Methadone
AUC0-24 h (ng/hour/mL) 288.5 272.2 0.94 291.2 1857 6.4
AUCinf (ng/hour/mL) 879.8 833.1 0.95 946.0 5674
a 6.0
Distribution T1/2 (hour) 8.3 7.0 0.84 6.7 15.5 2.3
Elimination T1/2 (hour) 48.5 50.4 1.0 52.4 52.4
a 1.0
Clearance (L/hour) 6.8 7.2 1.1 6.3 1.1
a 0.17
Vd (extrap) (L) 516.6 557.4 1.1 502.9 119.2
b 0.24
Vd (area) (L) 476.9 524.3 1.1 469.0 80.0
a 0.17
EDDP
AUC0-24 h (ng/hour/mL) 29.2 26.9 0.92 28.2 217.6 7.7
Observed Cmax (ng/mL) 1.6 1.3 0.81 1.6 10.5 6.6
AUCmethadone/AUCEDDP (0-12 h) 12.3 13.6 1.1 12.6 11.6 0.92
AUCmethadone/AUCEDDP (0-24 h) 9.9 10.1 1.0 10.3 8.5 0.83
EMDP
AUC0-24 h (ng/hour/mL) 2.7 2.0 0.74 1.5 10.4 6.9
Observed Cmax (ng/mL) 0.18 0.14 0.78 0.075 0.55 7.3
aEstimated using clearance and half-life calculated from the terminal elimination phase.
bEstimated using an extrapolation method based on the terminal elimination phase.
AUC = area under the plasma concentration time curve; AUC0-12 h = AUC from time 0 to 12 hours; AUC0-24 h = AUC from time 0 to 24 hours; AUCinf = AUC from
time 0 to infinity; ADR = our patient who experienced methadone overexposure; C = concentration; EDDP = 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
(primary metabolite of methadone); EMDP = 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline (secondary metabolite of methadone); N = our unaffected patient; T1/2 =
half-life; Vd = volume of distribution.
Table 3 Urinary pharmacokinetic parameters
Parameter N ADR
Dose A Dose B Ratio (B/A) Dose C Dose D Ratio (D/C)
Total urine volume (12 h, mL) 3132 3090 0.99 2488 267 0.11
Methadone
C (ng/mL) 52.6 54.6 1.0 88.6 1168 13.2
Total mass (μg) 165 169 1.0 220 312 1.4
Masstotal/AUC0-12 h (L/hour) 0.84 0.88 1.0 1.14 0.26 0.23
EDDP
C (ng/mL) 12.7 8.97 0.71 25.5 424 16.6
Total mass (μg) 39.7 27.7 0.70 63.4 113 1.8
C(methadone)/C(EDDP) 4.14 6.09 1.47 3.47 2.75 0.79
EMDP
C (ng/mL) 0.044 0.036 0.82 0.019 0.23 12.1
Total mass (μg) 0.14 0.11 0.79 0.047 0.062 1.3
AUC = area under the plasma concentration time curve; AUC0-12 h = AUC from time 0 to 12 hours; ADR = our patient who experienced methadone
overexposure; C = concentration; EDDP = 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (primary metabolite of methadone); EMDP = 2-ethyl-5-methyl-3,3-
diphenyl-1-pyrroline (secondary metabolite of methadone); N = our unaffected patient.
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these samples, an increase in total protein of 0.8 to 1.2 g/
dL (13% to 20%) was observed after dose D (Table 5).
U p o nf u r t h e ra n a l y s i so ft h ew h o l ep l a s m ap r o t e o m eb y
MS and relative quantification on the basis of label-free
spectra count, proteins that appeared to increase by two-
fold to fourfold during the adverse event (dose D) relative
to samples drawn at the equivalent time before (dose C)
included thrombin and its precursors, fibrinogen and its
precursors, complement factor 1, retinol-binding protein 4,
Shwachman-Bodian-Diamond syndrome protein, apolipo-
protein A-IV, serpin peptidase inhibitor, clade C and kini-
nogen 1 isoform 2 (data not shown).
In addition, serum concentrations of Na
+,C l
-,H C O 3
-,
blood urea nitrogen and creatinine in our ADR patient
were similar after both doses C and D (Table 5). Serum
lipid profiles were also similar before and after dosing
(data not shown).
Discussion
No interaction between methadone and letrozole had
been previously described. As a result of this adverse
event, the investigators immediately informed the IRB,
and put the trial on hold so that the cause of this adverse
event could be carefully investigated before any adjust-
ments were made to the trial design.
Unanticipated adverse events and fatalities caused by
methadone are a significant public health problem [4-6].
In this case report, we observed a marked increase in
plasma methadone concentrations and symptomatic
overexposure during co-administration of letrozole to a
single patient. Pharmacokinetic sampling was limited to
the first 24 hours after methadone dosing during the
a d v e r s ee v e n t ,b u tl a r g ep h a r m a c o k i n e t i cc h a n g e sw e r e
obvious. Since such large intra-individual changes may
have occurred in other patients, we estimated pharmaco-
kinetic parameters in order to explore the multiple possi-
ble causes of this adverse reaction.
First, although the data appear similar to those that
might be obtained as the result of a dosing error, the
amount of methadone remaining (single vial) before and
after this event were measured, and showed that the cor-
rect dose was used. The measured decrease in plasma fu
also makes an overdose seem impossible.
Second, the increase in methadone exposure was not
due to decreased metabolism, since the parent to meta-
bolite ratio in both plasma and urine decreased in our
patient.
Third, although the observed renal clearance of metha-
done significantly decreased (Table 3), reduced urinary
clearance was not the cause of the pharmacokinetic
changes observed in our patient since the total urinary
drug excreted over 12 hours was higher rather than
lower (Table 3).
Fourth, a small decrease in plasma volume could contri-
bute to the total increase in drug concentrations, but
serum electrolyte concentrations were similar after both
methadone doses, suggesting our patient was not
Table 4 Pharmacokinetic indices for plasma drug binding
at eight and 12 hours after methadone dosing
Parameter N ADR
Dose A Dose B Dose C Dose D
Methadone
Cfree, 8 h (ng/mL) 1.40 1.43 1.36 3.18
Cbound, 8 h (ng/mL) 8.45 8.22 8.72 78.0
Cfree, 12 h (ng/mL) 1.18 1.10 1.38 2.61
Cbound, 12 h (ng/mL) 6.86 6.74 7.40 58.8
Mean fu 0.14 0.14 0.15 0.04
fu ratio (A/B or C/D) 1.0 3.7
Vd (extrap) ratio 0.93 4.2
Vd (area) ratio 0.91 5.9
EDDP
Cfree, 8 h (ng/mL) 0.38 0.39 0.35 0.75
Cbound, 8 h (ng/mL) 0.72 0.75 0.61 6.56
Cfree, 12 h (ng/mL) 0.36 0.36 0.38 0.77
Cbound, 12 h (ng/mL) 0.71 0.66 0.69 7.37
Mean fu 0.34 0.35 0.36 0.10
fu ratio (A/B or C/D) 1.0 3.6
ADR = our patient who experienced methadone overexposure; C =
concentration; EDDP = 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
(primary metabolite of methadone); fu = fraction unbound; N = our unaffected
patient.
Table 5 Plasma protein concentrations and serum
chemistries at eight and 12 hours after methadone
dosing
Parameter N ADR
Dose A Dose B Dose C Dose D
Plasma proteins
Total protein8h(g/dL) 5.8 5.8 5.9 7.1
Albumin8h(g/dL) 3.4 3.5 3.4 3.8
AAG8h(mg/dL) 84 86 74 87
Total protein12 h (g/dL) 6.3 6.0 6.1 6.9
Albumin12 h (g/dL) 3.5 3.5 3.6 3.8
AAG12 h (mg/dL) 79 81 81 85
Serum chemistries
Na
+ (mmol/L) 144 139
Cl
- (mmol/L) 108 104
HCO3
- (mmol/L) 29 25
Blood urea nitrogen (mg/dL) 15 15
Creatinine (mg/dL) 0.78 0.72
AAG = a1-acid glycoprotein; ADR = our patient who experienced methadone
overexposure; N = our unaffected patient.
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volume cannot explain such large pharmacokinetic
changes.
Fifth, a change in transporter activity could in theory
increase plasma concentrations. The transport system
involved would have to counteract the rapid tissue diffu-
sion of methadone, a lipophilic drug, by stimulating
active transport of drug back into the plasma. While
this is theoretically possible, methadone has not been
shown to be vulnerable to transporter-mediated interac-
tions, and no effect of letrozole on drug transporters has
ever been described previously.
Sixth, we did observe a greater than fourfold decrease
in the estimated Vd (Table 4), which could result in
increased plasma and urine concentrations. Vd can be
described using the following equation:
Vd =E C F+ ￿ fu ￿ ICF
where ECF is the volume of the extra-cellular fluid, F
is the tissue-binding factor, fu is the plasma fraction
unbound, and ICF is the volume of the intra-cellular
fluid [8]. Relative to the terms in the second half of the
equation, ECF is a tiny contributor to the total Vd, espe-
cially for a drug with a large Vd such as methadone [9].
A decrease in tissue binding would not be expected to
reduce the fu in plasma, and cannot explain the increase
in plasma binding actually observed. In contrast, we
observed a decrease in fu due to increased plasma bind-
ing of methadone and its metabolites. A 3.7-fold change
in fu is of similar scale to that in Vd, and therefore can
account for most of the change. This change was also
accompanied by an increase in free methadone concen-
tration from 1.36 to 3.18 ng/mL in our affected patient.
The concentration of bound methadone increased from
8.72 to 78.0 ng/mL. While it is clear that the increased
concentration of unbound methadone contributed to
this symptomatic overexposure, the large change in
bound methadone may also have contributed by making
available a large reservoir of free drug for transport or
diffusion across the blood brain barrier. In addition, we
observed an increase in plasma protein concentrations,
and this is consistent with the increase in plasma
methadone binding. Of note, increased plasma protein
concentration has been previously reported to result in
decreased methadone fu [10].
Methadone has been shown to bind to a number of
different plasma proteins [11,12], including a1-acid gly-
coprotein (AAG), b-globulin [11] and lipoprotein frac-
tions [12]. When we examined changes in the plasma
proteome after dose D relative to dose C, we noted
small increases in the concentrations of albumin and
AAG, but prominent approximately twofold increases in
proteins in the coagulation pathway: in concentrations
of thrombin and its precursors, fibrinogen and its pre-
cursors and complement factor 1. Which of these might
b er e s p o n s i b l ef o rt h ec h a n g ei nm e t h a d o n eb i n d i n g
observed in our patient is at present unclear, but the
suggestion that changes in the coagulation pathway may
result in altered drug binding is an observation that may
have significance in some clinical scenarios.
The observed change in binding could not have been
due to the ingestion of other drugs, since neither of the
women were taking any medicine known to alter metha-
done binding. It is possible that letrozole caused these
changes in plasma protein concentrations via its effect on
estrogen concentrations [13,14]. While few data are avail-
able on such effects of estrogen depletion, it is clear that
estrogen supplementation with hormone replacement
therapy can decrease the concentrations of AAG [15]. It
follows that AAG may increase during therapy with an
aromatase inhibitor, as was observed in this case. It is
also possible that letrozole brings about these changes via
an ‘off-target’ effect, or that the change we observed in
methadone plasma binding is not due to letrozole, but
due to some uncontrolled factor.
Conclusions
This study illustrates a novel mechanism underlying
intra-individual changes in methadone pharmacokinetics
and pharmacodynamics: increases in plasma binding
that could result in increased effects. This mechanism
might help explain the unpredictability of methadone
effects. A similar mechanism may be responsible for
interactions with other drugs that alter the concentra-
tions of plasma binding proteins. The consequent
changes in Vd may represent important causes of clini-
cally meaningful drug interactions.
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